Cyfuse Biomedical K.K.

Company Snapshot

Founded: 2010
Entity Type: Public
Region: Japan
Headquarter: Tokyo, Japan
Key Geographics: Asia-Pacific
Corporate Address: South Tower-1F. Sumitomo Fudosan Tokyo Mita, 3-5-27, Mita Minato-ku, Tokyo 108-6301, Japan Tel. +81-3-6435-1885 www.en.cyfusebio.com

Company Overview

The Japanese bioprinting company comes from the term “fusing cells (cyto-).” The company generates tissues and organs by fusing cells through fusion activities in a variety of different aspects. Cyfuse’s specialty is a tissue fabrication process that doesn’t need any scaffold, such as polymers or collagen, to enable faster and more efficient tissue generation.

Cyfuse Biomedical K.K. In Reports

Current Bioprinting Prospects and Future Innovations: Global Markets

BCC Research detailed report on 3d bioprinting market trends includes global revenue ($ billion) for the base year (2024), estimated data for 2025, and forecast data for 2026 to 2030.

Bioprinting: Technologies and Global Markets

Global bioprinting technologies market should reach $5.0 billion by 2027 from $2.4 billion in 2022 at a CAGR of 16.2% for the forecast period of 2022-27.

3D Printed Medical Devices

BCC Research Market Report for 3D printed medical devices should grow from $1.7 billion in 2021 to $4.9 billion by 2026, at compound annual growth rate (CAGR) of 24.5%

Company's Business Segments

  • Regenerative Medicines : The company researched, developed, and commercialized tissue fabrication systems and cell-based products through its 3D tissue-engineering technology.

Applications/End User Industries

  • Healthcare
  • Pharmaceuticals
  • Tissue Engineering
  • Medicines
AI Sentiment